Company Registry

Pacific Northwest Biotechnology Inc (AKA:PNB)
Profile last edited on: 5/15/2019

NO Business Identifier is currently available for this company.
Year Founded
First SBIR Year
Latest SBIR Award
Program Status


Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

1425 NE Terre View Section D
Pullman, WA 99164
   (509) 334-2050
Multiple Locations:   
Congressional District:   05
County:   Whitman

Public Profile

Anchored in work that seems to have been undertaken by the principals and subsequently licensed from Washington University, Pacific Northwest Biotechnology (PNB) was established as a biopharmaceutical company organized around commercializing technology based on a unique ligand/receptor discovery platform. At the time of their SBIR Involvement, the company had a late pre-clinical stage small molecule with a demonstrated efficacy in animal models of breast, melanoma and anti-metastasis. PNB had other molecules in its patented library with clinical indications that have potentially large markets. The intent had been to monetize its drug pipeline in a manner that would enable the firm to manufacture/bring to market one/more of the most promising drugs in the pipeline. Market conditons of the period (2001-2010) made that difficult and the firm seems to have ceased operations c. 2013

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
Revenue Range
Less than .5M
VC funded?
Privately Held
Stock Info
IP Holdings

Awards Distribution by Agency

Most Recent SBIR Projects

Year Phase Agency Total Amount Project Title
2001 1 NIH $141,663
AT4 Antagonists as Antitumor Agents

Key People / Management

  Joseph W Harding -- CEO and Co-Founder

  John (Jay) W Wright -- Vice President and Co-Founder

SBIR firms in the news

There are no news available.